logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9790264 B1

PDFFull Text
Date of Patent:
Oct. 17, 2017

Filed:

Mar. 06, 2015

Compounds and methods for modulating pharmacokinetics

Applicant:

The Brigham and Women's Hospital, Inc., Boston, MA (US);

Inventors:

Richard T. Lee, Weston, MA (US);

Parth Patwari, Cambridge, MA (US);

James Pancoast, Cambridge, MA (US);

Assignee:

THE BRIGHAM AND WOMEN'S HOSPITAL, INC., Boston, MA (US);

Attorney:

Clark & Elbing LLP

Primary Examiner:

Elizabeth C Kemmerer

Assistant Examiner:

Regina M Deberry

Int. Cl.
CPC ...
C07K 7/00 (2006.01); C07K 14/475 (2006.01); C07K 14/54 (2006.01); C07K 14/65 (2006.01); A61K 38/04 (2006.01); A61K 38/18 (2006.01); A61K 38/20 (2006.01); A61K 38/30 (2006.01); A61K 39/35 (2006.01); C07K 14/635 (2006.01); A61K 38/29 (2006.01); A61K 38/22 (2006.01); A61K 38/37 (2006.01); A61K 9/00 (2006.01); A61K 47/48 (2006.01); C07K 14/705 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/65 (2013.01); A61K 9/0019 (2013.01); A61K 9/0021 (2013.01); A61K 38/18 (2013.01); A61K 38/185 (2013.01); A61K 38/2006 (2013.01); A61K 38/2242 (2013.01); A61K 38/29 (2013.01); A61K 38/30 (2013.01); A61K 38/37 (2013.01); A61K 47/48315 (2013.01); C07K 14/475 (2013.01); C07K 14/635 (2013.01); C07K 14/705 (2013.01); A61K 39/00 (2013.01); C07K 2319/21 (2013.01); C07K 2319/43 (2013.01);
Abstract

Methods and compositions are described for management of the pharmacokinetic properties of active agents, e.g., therapeutic moieties, by conjugating, fusing, or non-direct linkage of the active agent to one or more wild-type or modified heparin-binding peptides (HB). Compounds may be administered to tissues including skin. Contemplated uses include treatment of disease, allergen immunotherapy, and immunization. Other aspects relate to compositions, methods and kits comprising heparin-binding peptides (HB) fused or conjugated to the therapeutic agents.

Find Patent Forward Citations

Loading…